Results 31 to 40 of about 352 (104)

Maternal and Neonatal Outcomes of Immune Thrombocytopenia in Pregnancy: A Five‐Year Single‐Center Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Objectives Immune thrombocytopenia (ITP) during pregnancy presents unique management challenges. This study represents the first analysis of ITP outcomes during pregnancy in Qatar, aiming to assess maternal and neonatal outcomes at a tertiary care center.
Sarah A. Elkourashy, Hassan Magboul, Abdulrahman F. Al‐Mashdali, Mohammed Alnajjar, Naela AlMallahi, Elmustafa Abdalla, Dina Sameh Soliman, Sara Aldali, Manar E. Abdel‐Rahman Elhassan, Honar Cherif, Shehab F. Mohamed   +10 more
wiley   +1 more source

Long‐term efficacy and safety of romiplostim plus immunosuppressive therapy as first‐line treatment in patients with aplastic anaemia: 2‐year interim analysis of observational study of two clinical trials

British Journal of Haematology, EarlyView.
Jong Wook Lee, Kohei Hosokawa, Jun Ho Jang, Naoshi Obara, Masashi Sawa, Kensuke Usuki, Gaku Oshikawa, Masahiro Kizaki, Koji Nagafuji, Ting‐An Lin, Hitoshi Hanamoto, Yeung‐Chul Mun, Toshiro Kawakita, Kazunori Imada, June‐Won Cheong, Sung‐Soo Park, Takayuki Tabayashi, Masaru Gamou, Kenta Murotani, Hirohito Yamazaki   +19 more
wiley   +1 more source

Severe Thrombocytopenia Is Associated With Bleeding in Hepatocellular Carcinoma Patients Receiving Antiangiogenic Therapy

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 140-149, June 2026.
Thrombocytopenia is common in hepatocellular carcinoma and may increase bleeding risk during antiangiogenic therapy, yet the clinically relevant platelet threshold remains uncertain. We found that a baseline platelet count < 50 × 109/L was associated with bleeding; patients below this cutoff had a substantially higher bleeding rate than those with ...
Jun Tie, Zhengcai Liu, Xulong Yuan, Kai Li, Jing Niu, Jiao Xu, Li Xu, Yongquan Shi, Shuqiang Yue   +8 more
wiley   +1 more source

Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes

Journal of Veterinary Internal Medicine
Background Romiplostim, a thrombopoietin analog, is commonly used to treat immune‐mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited.
Min‐Ok Ryu, Jin‐Kyung Kim, Ju‐Hyun An, Kyoung‐Won Seo, Ye‐In Oh, Hwa‐Young Youn   +5 more
doaj   +1 more source

Efficacy and safety of high doses of eltrombopag for treating adult immune thrombocytopenia: Results from a multicentre retrospective cohort study

British Journal of Haematology, EarlyView.
Salomé Dahan, Stéphanie Guillet, Olivier Fain, Delphine Gobert, Stéphane Cheze, Florent Broca, Bertrand Godeau, Marc Michel   +7 more
wiley   +1 more source

Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL‐AVA 3.5 study

British Journal of Haematology, Volume 208, Issue 6, Page 2185-2193, June 2026.
Summary Real‐world data on treatment response after switching between thrombopoietin receptor agonists are limited for patients with immune thrombocytopenia (ITP). The objective of this study is to describe treatment patterns and outcomes in patients with primary ITP who switched from eltrombopag (ELT) or romiplostim (ROMI) to avatrombopag (AVA).
Caroline Piatek, Abiola Oladapo, Scott Kolodny, Michael Vredenburg, Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Hillary Maitland   +8 more
wiley   +1 more source

Validation of a biolayer interferometry-based method for the determination of binding (total) antibodies to romiplostim in human serum

Биопрепараты: Профилактика, диагностика, лечение
INTRODUCTION. Romiplostim treatment of patients with idiopathic thrombocytopenic purpura is associated with formation of anti-drug antibodies (ADA), which often leads to the serious adverse events.
A. A. Agafonova, M. V. Zhilyaeva, I. V. Lyagoskin, A. A. Kazarov, A. E. Lisova, R. R. Shukurov   +5 more
doaj   +1 more source

Pragmatic Clinical Trial of Fostamatinib as Second‐Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trial

eJHaem, Volume 7, Issue 4, August 2026.
Amber Afzal, Robert Kribs, Sumit Sawhney, Mohit Narang, Frances Blevins, Robert Numerof, Francois Di Trapani, Sherry Ladha, Ruchika Goel   +8 more
wiley   +1 more source

Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy

Клиническая онкогематология, 2017
Background. New medications, thrombopoietin mimetics which were recently introduced into clinical practice allowed to achieve clinical response in patients with chronic glucocorticoid-resistant idiopathic thrombocytopenic purpura (ITP). However, the high
Vasilii Anatol’evich Shuvaev, S. V. Voloshin, A. K. Hadzhidis, A. V. Chechetkin   +3 more
doaj   +1 more source

Refractory autoimmune hemolytic anemia with poor erythropoietic compensation in combined immunodeficiency: A case series

Pediatric Allergy and Immunology, Volume 37, Issue 8, August 2026.
Letizia Baldini, Mattia Moratti, Alessandro Ruggi, Francesco Licciardi, Fraia Melchionda, Maura Fois, Maria Elena Cantarini, Elena Facchini, Veronica Barat, Giovanni Del Borrello, Bruno Fattizzo, Elena Sabattini, Clara Bertuzzi, Riccardo Masetti, Francesca Conti   +14 more
wiley   +1 more source